COMMUNIQUÉS West-GlobeNewswire

-
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
24/03/2025 -
NativePath Native Hydrate: The Senior Hydration Solution That Supports Energy, Bladder Health & Brain Function
24/03/2025 -
TOMI Secures $450,000 Contract for Custom Engineered System (CES) Installation
24/03/2025 -
Philips convenes the Annual General Meeting of Shareholders 2025
24/03/2025 -
Abivax Announces Full Year 2024 Financial Results
24/03/2025 -
Press Release: Availability of the Q1 2025 Aide mémoire
24/03/2025 -
Communiqué de presse : Mise en ligne du document « Q1 2025 Aide mémoire »
24/03/2025 -
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
24/03/2025 -
DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requises pour la demande de BLA du patch Viaskin® Peanut chez les enfants de 4-7 ans, accélérant ainsi au premier semestre 2026 le dépôt de la demande…
24/03/2025 -
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
24/03/2025 -
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
24/03/2025 -
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
24/03/2025 -
Valneva répond à l'appel du gouvernement français pour la fourniture du vaccin IXCHIQ® contre l'épidémie de chikungunya à La Réunion
24/03/2025 -
Opthea Announces COAST Phase 3 Trial Topline Results
24/03/2025 -
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
24/03/2025 -
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
24/03/2025 -
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
23/03/2025 -
Ever Joint Benefits: How This Supplement Supports Flexibility and Weight Loss
22/03/2025 -
Best Steroids For Bodybuilding (Muscle Growth & Bulking) From CrazyBulk in 2025
22/03/2025
Pages